3,115 Shares in Agilent Technologies, Inc. $A Acquired by Versor Investments LP

Versor Investments LP bought a new position in shares of Agilent Technologies, Inc. (NYSE:A) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,115 shares of the medical research company’s stock, valued at approximately $364,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC grew its holdings in Agilent Technologies by 286.2% in the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock valued at $29,000 after buying an additional 186 shares in the last quarter. Sunbelt Securities Inc. lifted its position in shares of Agilent Technologies by 640.0% during the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock worth $30,000 after buying an additional 192 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Agilent Technologies during the 1st quarter worth $30,000. Opal Wealth Advisors LLC bought a new stake in shares of Agilent Technologies during the 1st quarter worth $31,000. Finally, Wood Tarver Financial Group LLC bought a new position in Agilent Technologies in the fourth quarter valued at about $34,000.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Agilent Technologies Stock Performance

NYSE:A opened at $118.9710 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84. The firm has a market cap of $33.80 billion, a price-to-earnings ratio of 29.38, a PEG ratio of 3.64 and a beta of 1.22. The business’s fifty day moving average is $117.83 and its 200 day moving average is $117.87.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The business had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.63 billion. During the same period in the previous year, the business earned $1.22 earnings per share. The firm’s revenue was up 6.0% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. Research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Leerink Partners raised their price objective on Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 30th. UBS Group decreased their target price on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research note on Thursday, May 29th. Barclays increased their price target on Agilent Technologies from $115.00 to $125.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 24th. Robert W. Baird decreased their price target on Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating for the company in a report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. decreased their price target on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 29th. Seven analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $139.77.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.